Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals' Revenue history spans 5 years, with the latest figure at $820188.0 for Q4 2025.

  • For Q4 2025, Revenue fell 26.22% year-over-year to $820188.0; the TTM value through Dec 2025 reached $4.5 million, down 6.73%, while the annual FY2025 figure was $4.9 million, 7.5% up from the prior year.
  • Revenue reached $820188.0 in Q4 2025 per INM's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.3 million in Q2 2023 to a low of $265092.0 in Q4 2021.
  • Average Revenue over 5 years is $982686.4, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Revenue: skyrocketed 348.96% in 2023, then crashed 44.48% in 2024.
  • A 5-year view of Revenue shows it stood at $265092.0 in 2021, then soared by 77.22% to $469783.0 in 2022, then surged by 163.99% to $1.2 million in 2023, then decreased by 10.36% to $1.1 million in 2024, then fell by 26.22% to $820188.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Revenue are $820188.0 (Q4 2025), $1.1 million (Q3 2025), and $1.3 million (Q2 2025).